ARTICLE | Finance

The Cystic Fibrosis Powerhouse: Vertex 

Back to School 2023 case study: How Vertex kept raising the bar to dominate a therapeutic space

September 1, 2023 4:45 PM UTC

A long, winding road got Vertex Pharmaceuticals to the position it has now occupied for the past 10 years: dominating the market for cystic fibrosis therapies and driving the biotech’s valuation into the stratosphere of megacaps.

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is a Back to School 2023 case study of how a company can drive material growth by commandeering a niche corner of the market; in this case, the orphan disease of cystic fibrosis...

BCIQ Company Profiles

Vertex Pharmaceuticals Inc.